Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.35
-0.09 (-0.67%)
Feb 21, 2025, 4:00 PM EST - Market closed
Dr. Reddy's Laboratories Employees
Dr. Reddy's Laboratories had 27,048 employees as of March 31, 2024. The number of employees increased by 1,185 or 4.58% compared to the previous year.
Employees
27,048
Change (1Y)
1,185
Growth (1Y)
4.58%
Revenue / Employee
$134,487
Profits / Employee
$23,189
Market Cap
11.08B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 27,048 | 1,185 | 4.58% |
Mar 31, 2023 | 25,863 | 1,068 | 4.31% |
Mar 31, 2022 | 24,795 | 2,056 | 9.04% |
Mar 31, 2021 | 22,739 | 1,089 | 5.03% |
Mar 31, 2020 | 21,650 | -316 | -1.44% |
Mar 31, 2019 | 21,966 | -1,558 | -6.62% |
Mar 31, 2018 | 23,524 | 853 | 3.76% |
Mar 31, 2017 | 22,671 | 496 | 2.24% |
Mar 31, 2016 | 22,175 | 1,802 | 8.85% |
Mar 31, 2015 | 20,373 | 1,952 | 10.60% |
Mar 31, 2014 | 18,421 | 1,804 | 10.86% |
Mar 31, 2013 | 16,617 | 1,417 | 9.32% |
Mar 31, 2012 | 15,200 | 277 | 1.86% |
Mar 31, 2011 | 14,923 | 1,468 | 10.91% |
Mar 31, 2010 | 13,455 | 2,227 | 19.83% |
Mar 31, 2009 | 11,228 | 1,653 | 17.26% |
Mar 31, 2008 | 9,575 | 555 | 6.15% |
Mar 31, 2007 | 9,020 | 1,495 | 19.87% |
Mar 31, 2006 | 7,525 | 1,390 | 22.66% |
Mar 31, 2005 | 6,135 | -20 | -0.32% |
Mar 31, 2004 | 6,155 | 303 | 5.18% |
Mar 31, 2003 | 5,852 | 409 | 7.51% |
Mar 31, 2002 | 5,443 | 314 | 6.12% |
Mar 31, 2001 | 5,129 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
RDY News
- 16 days ago - Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe - Business Wire
- 17 days ago - Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. - PRNewsWire
- 24 days ago - Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns - Seeking Alpha
- 4 weeks ago - Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Dr. Reddy's Q3 & 9MFY25 Financial Results - Business Wire
- 3 months ago - Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma - Business Wire
- 3 months ago - Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market - Business Wire
- 3 months ago - Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript - Seeking Alpha